Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) is a clinical-stage biopharmaceutical company developing orally administered antiviral medicines for serious viral diseases. Its lead program combines bemnifosbuvir, a nucleotide analog, with ruzasvir, an NS5A inhibitor, for chronic hepatitis C virus (HCV) infection; the… From the company’s description.
In fiscal 2025, Atea Pharmaceuticals, Inc. reported a net loss of $158.35M. Operations used $132.03M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Atea Pharmaceuticals, Inc. does
In the company’s own words
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) is a clinical-stage biopharmaceutical company developing orally administered antiviral medicines for serious viral diseases. Its lead program combines bemnifosbuvir, a nucleotide analog, with ruzasvir, an NS5A inhibitor, for chronic hepatitis C virus (HCV) infection; the company is also developing AT-587 for chronic hepatitis E virus (HEV) infection, particularly in immunocompromised patients. Atea’s proprietary nucleos(t)ide platform supports discovery of potential treatments for single-stranded RNA viruses. Its HCV regimen is being evaluated in two Phase 3 trials, one in the United States and Canada and one elsewhere, each designed to enroll approximately 880 patients. The company’s activities center on discovering and developing product candidates, rather than operating commercial product lines; it has no products generating commercial revenue. Atea also in-licensed ruzasvir from an affiliate of Merck in 2021.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 1593899
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Atea Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Atea Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Atea Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Atea Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Atea Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”